PDS Biotechnology Corporation · NASDAQ:PDSB
PDS Biotechnology — Investor Presentation (November 2020)
19 slides from PDS Biotechnology's investor presentation, November 2020
Slide 1: Corporate Overview November 2020
CORPORATE OVERVIEW NOVEMBER 2020 Frank Bedu-Addo Ph.D. President & CEO Nasdaq: PDSB A new generation of multi-functional cancer immunotherapies
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation (“PDSB”), and its businesses, business prospects, strategies and plans, including but not limited to statements regarding anticipated pre-clinical and clinical drug development activi
Slide 3: PDS Biotech is a clinical stage biotechnology company developing immunotherapies on Versamune platform
PDS Biotech is a clinical stage biotechnology company developing a pipeline of immunotherapies based on the proprietary Versamune® platform CORPORATE OVERVIEW VERSAMUNE® PLATFORM PIPELINE • Biopharma developing novel • Versatile, potent T-cell-activating treatments for cancer and T-cell platform dem
Slide 4: Versamune-based pipeline developed in partnership with leaders in immuno-oncology
PDS Biotech’s robust Versamune®-based pipeline being developed in partnership with the leaders in immuno-oncology Nasdaq: PDSB Reference: Data on file. 4
Slide 5: Executive team has demonstrated success in development and commercialization of pharmaceutical products
PDS Biotech executive team has demonstrated success in the development and commercialization of leading pharmaceutical products • Senior executive experience with management of strategy and Frank Bedu-Addo, PhD execution at both large pharma and biotechs Chief Executive Officer • Notable drug develo
Slide 6: Introduction to the Versamune Platform
Introduction to the ® Versamune Platform
Slide 7: Versamune is designed to induce a robust and targeted anti-tumor response in vivo
Versamune® is designed to induce a robust and targeted anti-tumor response in vivo when administered with a tumor-associated antigen Versamune® + Tumor- associated proteins (antigens) Promotes uptake of vaccine Promotes antigen processing Activates Type I Interferon or immunotherapy and and presenta
Slide 8: Versamune possesses key characteristics of a safe and effective immunotherapeutic treatment
Versamune® posses the key characteristics of a safe and effective immunotherapeutic treatment Versamune®-based Checkpoint Traditional Cancer Immunotherapies Inhibitors Vaccines Induction of high levels of active CD8+ (killer) T-cells ✓ Induction of high levels of CD4+ (helper) T- cells ✓ ✓ Ability t
Slide 9: Versamune-induced killer T-cells may eradicate HPV-positive tumors after a single dose
Greater quantity and quality of Versamune®-induced killer T-cells may result in unique ability to eradicate HPV-positive tumors after a single dose Produces > 10-fold number of highly potent (polyfunctional) killer T-cells vs. other T-cell technologies 500 # of Antigen-Recognizing T-Cells IFN-γ Spot
Slide 10: Preclinical T-cell induction and regression efficacy replicated in Phase 1 study
Preclinical T-cell induction and regression efficacy replicated in Phase 1 study, demonstrating powerful in-vivo CD8+ T-cell response in humans Overcomes key limitation of immuno-oncology: > 15-fold increase in IFN-γ inducing T-cells and > 20-fold increase in circulating dual INF-γ and Granzyme-b in
Slide 11: Versamune has demonstrated compatibility with a wide array of tumor and pathogenic antigens
Versamune® has demonstrated immunological compatibility with a wide array of tumor and pathogenic antigens • Today, 4 tumor antigens are being utilized with the Versamune® platform, more than 75 tumor antigens have been identified • We are currently progressing two Versamune®-based infectious diseas
Slide 12: PDS0101 Clinical Development
PDS0101 Clinical Development
Slide 13: PDS0101 is designed to treat cancers caused by HPV
PDS0101 is designed to treat cancers caused by human papillomavirus (HPV) US annual HPV-associated cancer incidence1 • Approximately 43,000 patients are diagnosed with HPV-associated cancers Females (24,391) Males (18,280) annually in the US • Incidence rate is growing despite increased use of HPV p
Slide 14: Value creation strategy: combination studies for rapid proof-of-concept and risk mitigation
Value creation strategy: Focus on combination studies for rapid proof-of- concept and risk mitigation PDS0101 has demonstrated strong potential for efficacy as a monotherapy PDS0101 is being investigated in two Phase 2 trials in combination therapies to enhance the clinical benefit of treatments tha
Slide 15: Phase 2 studies of PDS0101 in combination therapy
Phase 2 studies of PDS0101 in combination therapy will evaluate efficacy and safety in a range of advanced HPV cancers Phase 2 Open Label Study Partner Important Considerations Initiation (Safety and Efficacy) • Recurrent/metastatic HPV16-associated head & neck cancer – First line • Objective is to
Slide 16: Looking Forward
Looking Forward
Slide 17: Financial position to support PDS0101 projected milestones through mid-2022
Financial position to support PDS0101 projected milestones through mid-2022* Nasdaq: PDSB *Based on current enrollment, modeling, enrollment and forecast modeling as of November 2020. Subject to change. 17
Slide 18: Well positioned for near-term value appreciation
Well positioned for near-term value appreciation Key Advantages and Differentiators PIPELINE • Enhanced anti-cancer efficacy: Early clinical data and preclinical data suggest potentially superior efficacy, safety and versatility of the platform • Potential for near-term value appreciation: PDS0101 p
Slide 19: A new generation of multi-functional cancer immunotherapies
Nasdaq: PDSB A new generation of multi-functional cancer immunotherapies
PDS Biotechnology — Investor Presentation (November 2020) on 6ix